Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Robot suit aims to get paralyzed patients back on their feet

NCT ID NCT07669181

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a robotic exoskeleton called ReWalk can help people with complete spinal cord injury below T4 walk and improve their health. Fifty participants will either use the exoskeleton or receive standard physical therapy. The goal is to see if the device improves walking speed, bone density, independence, and overall well-being.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ReWalk lower-limb exoskeleton
What this could lead to
If successful, this could show that exoskeleton training improves mobility, bone health, and quality of life for people with spinal cord injury.
What could go wrong
This is a small, early-stage study with only 50 participants, so results may not apply to everyone. The device requires significant upper body strength and training, and not all patients will benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2017

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Complete spinal cord injury below thoracic vertebra level 4 with paraparesis or paraplegia * At least 4 months since the spinal cord injury * Adequate arm and shoulder muscle condition to use forearm crutches * Adequate bone density; if needed confirmed by dual energy X ray absorptiometry: hip T score greater than minus 3.5 * Intact skeletal system; stable or stabilized spinal injury, with no fresh, non consolidated fracture that would affect device use or walking * Able to stand confidently using a standing device similar to EasyStand * Good general health * Body dimensions compatible with the device: height 160 to 190 centimeters; femur length 43.5 to 56 centimeters; tibia length 36 to 48.5 centimeters * Body weight maximum 100 kilograms * Adequate lower limb range of motion: physiological ankle position; hip extension 0 degrees; knee contracture less than 10 degrees Exclusion Criteria: * History of severe neurological disease other than traumatic spinal cord injury (for example multiple sclerosis, cerebral palsy, amyotrophic lateral sclerosis, traumatic brain injury) * Serious active illness (for example infection) or reduced exercise tolerance due to cardiovascular or pulmonary disease * Abdominal or thoracic condition that prevents exoskeleton use (for example enterostoma, chest deformity) or pressure ulcer that interferes with fitting or use * Severe spasticity (Modified Ashworth Scale grade 4) * Unstable spine, or limb/pelvic condition limiting load bearing (for example non healed fracture, post amputation state) * Heterotopic ossification that impairs joint mobility beyond allowed limits * Significant contractures: ankle plantar flexion contracture greater than 0 degrees; knee contracture greater than 10 degrees; hip flexion contracture 20 degrees * Psychiatric or cognitive impairment that limits safe device handling or study participation * Pregnancy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Spinal cord injury are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Department of Neurosurgery

    Pécs, Baranya, 7624, Hungary

More trials for these conditions

Other studies related to the condition(s) this trial covers.